,36 However, when it comes to gene-based therapies that are aimed to restore normal GALT activity in disease-relevant tissues, the in situ PK/PD assessments become challenging because the affected organs in galactosemia (i.e., liver, brain, and ovary) are not amendable to repeated sample collections. The gene discussed is GALT; the disease is classic galactosemia.